Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia

• Published in: AIDS (London) Vol. 29; no. 7; pp. 853 - 856
• Main Authors: Campillo-Gimenez, Laure, Assoumou, Lambert, Valantin, Marc-Antoine, Pajanirassa, Priyadharshini, Villemonteix, Juliette, Soulié, Cathia, Marcelin, Anne-Geneviève, Costagliola, Dominique, Capeau, Jacqueline, Autran, Brigitte, Katlama, Christine, Guihot, Amélie
• Format: Journal Article
• Language: English
• Published: England 24-04-2015
• Subjects: AIDS/HIV; Anti-HIV Agents - therapeutic use; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - immunology; Cyclohexanes - therapeutic use; Female; HIV Infections - drug therapy; HIV Infections - immunology; Humans; Lentivirus; Lymphocyte Activation; Male; Middle Aged; Monocytes - immunology; Raltegravir Potassium - therapeutic use; Retroviridae; RNA, Viral - blood; Treatment Outcome; Triazoles - therapeutic use; Viral Load; Viremia
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/QAD.0000000000000626

Immunovirological consequences of a switch to a maraviroc/raltegravir dual therapy were analyzed in 16 HIV-infected patients with persistent viral load below 50 copies/ml. At 26-week postswitch, the CD4/CD8 ratio decreased and the CD8 T-cell activation increased. A decrease in classical monocytes was associated with a shift toward a proinflammatory monocyte profile and negatively correlated with ultrasensitive viral load. Thus, this therapeutic switch induced a proinflammatory profile probably driven by a slight loss of virus control.